ALL Induction Therapy
For adults with Philadelphia chromosome-negative (Ph-negative) B-cell ALL, use a pediatric-inspired regimen with vincristine, corticosteroid, asparaginase, and anthracycline as the standard induction backbone, while for pediatric patients, use a 4-drug regimen (vincristine, anthracycline, corticosteroid, asparaginase) for high-risk disease or 3-drug regimen (without anthracycline) for NCI standard-risk disease. 1, 2
Adult Induction Regimens
Preferred Backbone Components
The core induction therapy consists of:
- Vincristine
- Corticosteroids (prednisone or dexamethasone)
- Anthracyclines (daunorubicin or doxorubicin)
- Asparaginase (pegaspargase or calaspargase)
Specific Adult Regimen Options
Pediatric-Inspired Regimens (Preferred for AYA and younger adults):
- GRAALL-2005 regimen: Vincristine, daunorubicin, prednisone, L-asparaginase, and cyclophosphamide achieved 2-year EFS of 65% when combined with rituximab for CD20-positive disease 1
- Linker 4-drug regimen: Vincristine, daunorubicin, prednisone, and asparaginase with 5-year OS of 47% in adults (median age 27 years) 1
- USC ALL trial (CCG-1882 adaptation): Daunorubicin, vincristine, prednisone, methotrexate with augmented pegaspargase (2,000 IU/m² IV, lower than FDA-approved 2,500 IU/m²) achieved 7-year OS of 51% 1
Traditional Adult Regimens:
- Hyper-CVAD: Cyclophosphamide, vincristine, doxorubicin (Adriamycin), dexamethasone achieved 5-year OS of 42% in Ph-negative ALL 1
- MRC UKALL XII/ECOG E2993: Phase I with vincristine, daunorubicin, prednisone, L-asparaginase for 4 weeks, followed by Phase II with cyclophosphamide, cytarabine, oral mercaptopurine, intrathecal methotrexate for 4 weeks. 5-year OS was 54% for standard-risk and 29% for high-risk disease 1
- CALGB regimen: 5-drug combination adding cyclophosphamide to the 4-drug backbone 2
Age-Specific Considerations
Adults ≤45 years: Pediatric-inspired regimens with intensified vincristine, prednisone, and asparaginase show superior outcomes (42-month OS of 66%) compared to older patients 1
Adults >45 years: Higher therapy-related mortality (23% vs 5%) and deaths in first CR (22% vs 5%) with pediatric-inspired regimens. The 42-month OS drops to 41% in this age group 1
Adults ≥60 years: Consider less intensive approaches or novel immunotherapy-based regimens due to high treatment-related mortality (up to 50% with intensive regimens) 1, 3
Pediatric Induction Regimens
Risk-Stratified Approach
NCI Standard-Risk Disease (3-drug induction):
- Vincristine
- Corticosteroid
- Asparaginase
- No anthracycline 2
High-Risk Disease (4-drug induction):
- Vincristine
- Anthracycline (daunorubicin or doxorubicin)
- Corticosteroid
- Asparaginase 2
Corticosteroid Selection
Dexamethasone is preferred over prednisone for its superior CNS penetration and reduced isolated CNS relapse risk, though it carries higher toxicity (osteonecrosis, infection) 2. COG uses dexamethasone 6 mg/m²/day for 28 days rather than the higher-dose 10 mg/m²/day for 21 days schedule 2.
Asparaginase Formulations
Calaspargase is preferred for patients ≥1 month through 21.5 years (if available) due to longer half-life and enhanced stability compared to pegaspargase. As of December 2022, pegaspargase ordering is restricted to this age group in the United States 2. ERW-rywn is reserved for patients with allergic reactions to calaspargase or pegaspargase 2.
Critical Supportive Care Elements
Growth Factor Support
G-CSF administration starting 4 days after induction significantly shortens neutropenia and thrombocytopenia duration, increases CR rates, and reduces induction mortality (though OS/DFS benefits remain unclear) 1
CNS Prophylaxis
All induction regimens must include CNS prophylaxis with intrathecal chemotherapy (typically methotrexate or cytarabine) 1, 2
CD20-Positive Disease
Add rituximab to induction for CD20-positive Ph-negative ALL (CD20 expression >20% of blasts). The GRAALL-2005 study demonstrated improved 2-year EFS (65% vs 52%, HR 0.66, p=0.04) with rituximab addition 1
Common Pitfalls and Toxicity Management
4-drug vs 3-drug induction in pediatrics: The 4-drug regimen significantly increases risks of sepsis (HR 2.16), hypoxia (HR 2.08), hyperbilirubinemia (HR 2.48), hyperglycemia (HR 2.65), thromboembolic events (HR 4.50), and hyponatremia (HR 7.88), with 8 additional inpatient days compared to 3-drug induction 4
Asparaginase dosing in adults: Use lower doses (2,000 IU/m² vs 2,500 IU/m²) and extend dosing intervals to ≥4 weeks to account for differences in drug enzymatic activity and reduce toxicity 1
Avoid excessive dose intensification: Attempts to intensify induction with intermediate-dose cytarabine and idarubicin resulted in unacceptable 29% treatment-related mortality with significant hepatic, gastrointestinal, infectious, and neurologic toxicity 5
Dexamethasone toxicity: Monitor closely for osteonecrosis and infection, particularly at doses of 10 mg/m²/day. The OS advantage over prednisone is not conclusively established except in T-ALL subsets 2
Expected Outcomes
Complete remission rates:
- Pediatric patients: 95-98%
- Adults with pediatric-inspired regimens: 78-88%
- Adults with traditional regimens: 71-93% 1, 6, 7
Long-term survival: